{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:59Z","timestamp":1786649879791,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Breast cancer is the second leading cause of cancer-related mortality despite the staggering improvement in cancer therapeutics. So far, published data illustrate endocrine therapy as the cornerstone treatment for patients with hormone receptor-positive metastatic breast cancer. Unfortunately, most patients eventually develop resistance to this treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The purpose of this study is to evaluate the efficacy of mammalian target of rapamycin inhibition in reversing hormone resistance in the Lebanese breast cancer patients. Efficacy of the intervention according to the independent factors and notable side effects encountered were the primary points of the evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, fifty patients received the combination of everolimus and exemestane. The mean age of the study population was 61 \u00b1 11 years. Sensitivity to hormonal therapy before the start of the combination treatment was estimated at 64%. Response rate was 14%, and all patients were partial responders. After regular interval evaluation, the median progression-free survival was 5.2 months since the initiation of therapy. The main toxicities associated with the combination were stomatitis (22%), myalgia (22%), skin toxicity (8%), and hyperglycemia (4%), all Grades 1 and 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Everolimus has been shown to be effective in overcoming hormonal resistance in Lebanese breast cancer patients with results inferior to those reported in the BOLERO-2 population. The particular differences in molecular and pathological aspects of breast cancer in our region should stimulate the extensive research for a better understanding of the particular pattern of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.183552","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"1112-1116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience"],"prefix":"10.4103","volume":"14","author":[{"given":"Tarek","family":"Assi","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"El Rassy","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Tabchi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Chebib","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moussa","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"El Karak","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Farhat","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp0708307","article-title":"\u201cWesternizing\u201d women's risks? Breast cancer in lower-income countries","volume":"358","author":"Porter","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/0008-5472.CAN-08-4450","article-title":"PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer","volume":"69","author":"Crowder","year":"2009","journal-title":"Cancer Res"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR+breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"R11-20260109","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/490631","article-title":"Breast cancer in low-and middle-income countries: An emerging and challenging epidemic","author":"Tfayli","year":"2010","journal-title":"J Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(13)70165-7","article-title":"Breast cancer in Arab populations: Molecular characteristics and disease management implications","volume":"14","author":"Chouchane","year":"2013","journal-title":"Lancet Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1634\/theoncologist.12-6-636","article-title":"Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy","volume":"12","author":"Tacca","year":"2007","journal-title":"Oncologist"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","article-title":"Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR+, HER2-advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R17-20260109","first-page":"2341","article-title":"Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: Observations from a phase III clinical trial","volume":"21","author":"Peterson","year":"2013","journal-title":"Support Care Cancer"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: A structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejca.2011.06.054","article-title":"An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy","volume":"48","author":"Gr\u00fcnwald","year":"2012","journal-title":"Eur J Cancer"},{"key":"R22-20260109","first-page":"332","article-title":"Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience","volume":"29","author":"Cauley","year":"2011","journal-title":"In ASCO Annual Meeting Proceedings"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.breast.2015.09.002","article-title":"Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study","volume":"24","author":"Chocteau-Bouju","year":"2015","journal-title":"Breast"},{"issue":"26 Suppl 6","key":"R24-20260109","first-page":"vi15","article-title":"Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: A single institution experience","volume":"1","author":"Ferrarini","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"R25-20260109","doi-asserted-by":"crossref","first-page":"vi13","DOI":"10.1093\/annonc\/mdv336.34","article-title":"Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)","volume":"26","author":"Moscetti","year":"2015","journal-title":"Ann Oncol"},{"key":"R26-20260109","first-page":"e11579","article-title":"Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa:First efficacy and updated safety results from the phase IIIb EVEREXES study. Vol. 33","author":"Im","year":"2015","journal-title":"ASCO Annual Meeting Proceedings"},{"issue":"26 Suppl 6","key":"R27-20260109","first-page":"vi20","article-title":"Everolimus in ER+\/HER-2 negative metastatic breast cancer (MBC): What we have learned from two years of clinical practice. A single Institution experience","volume":"1","author":"Della Mora","year":"2015","journal-title":"Ann Oncol"},{"key":"R28-20260109","first-page":"578","article-title":"Breast cancer treatment with everolimus and exemestane for ER+women: Results of the first interim analysis of the noninterventional trial BRAWO. Vol. 32","author":"Lueftner","year":"2014","journal-title":"In ASCO Annual Meeting Proceedings"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicenter, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:29Z","timestamp":1786647569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.183552","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}